Developing Treatments for Chronic Kidney Disease in the 21st Century

Area of Science:

• Nephrology
• Pharmacology
• Clinical Trials

Background:

• Chronic kidney disease (CKD) presents a significant and growing global health challenge.
• The development pipeline for novel CKD therapeutics is notably sparse.
• Recent high-cost Phase 3 trials have yielded disappointing results in improving renal outcomes, impacting pharmaceutical investment.

Purpose of the Study:

• To review the current landscape of therapeutic development for chronic kidney disease.
• To identify key challenges hindering the progress of CKD clinical trials.
• To highlight promising therapeutic avenues and strategies for future trial success.

Main Methods:

• Review of existing literature on CKD pathogenesis and therapeutic development.
• Analysis of recent Phase 3 clinical trial outcomes in CKD.
• Identification of therapeutic classes currently under investigation for CKD.

Main Results:

• Several therapeutic classes show promise, including mineralocorticoid-receptor antagonists, SGLT2 inhibitors, anti-inflammatory agents, and drugs targeting oxidative injury.
• Significant barriers to trial success include poor patient, physician, and payer awareness of CKD.
• Low trial enrollment rates impede the efficient and successful implementation of clinical studies.

Conclusions:

• Despite setbacks, several promising therapeutic strategies for CKD are in development.
• Improving awareness of CKD among the public, policymakers, and the medical community is crucial for enhancing trial enrollment.
• Future success in CKD therapeutic trials hinges on a deeper understanding of disease mechanisms and improved patient recruitment strategies.